Clinical Trials Logo

Clinical Trial Summary

Actual studies suggest that a calcium activated chlorid channel (TMEM16A) may play a relevant role in the pathogenesis of pulmonary arterial hypertension (PAH). The inhibition of this channel led to pulmonary vasorelaxation in preclinical studies. Benzbromarone is a well known inhibitor of the TMEM16A channel and is used in patients with gout.

In this pilot study the investigators plan to investigate if Benzbromarone has an acute effect on the pulmonary arteries in humans. This will be investigated within the frame of a right heart catheterization performed in patients with known PAH due to clinical reasons. The investigators hypothesize that the application of Benzbromarone leads to pulmonary vasodilation, which can be recognized by the decrease in pulmonary vascular resistance. In addition, the change in pulmonary and systemic arterial pressure, pulmonary arterial wedge pressure, heart rate and arterial oxygen saturation will be assessed. Due to clinical reasons patients will receive NO (15 ppm) during right heart catheterization. Hemodynamic changes upon NO and Benzbromarone may be compared.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Familial Primary Pulmonary Hypertension
  • Hypertension
  • Idiopathic Pulmonary Arterial Hypertension

NCT number NCT02790450
Study type Interventional
Source Medical University of Graz
Contact
Status Completed
Phase Phase 2
Start date October 2015
Completion date August 2016

See also
  Status Clinical Trial Phase
Recruiting NCT01884051 - Hormonal, Metabolic, and Signaling Interactions in PAH
Completed NCT00626028 - Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing Phase 3
Recruiting NCT05584722 - Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Completed NCT01590108 - The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects Phase 1
Recruiting NCT05493371 - Empagliflozin in Pulmonary Arterial Hypertension Phase 2
Recruiting NCT03933579 - The PAH Platform for Deep Phenotyping in Korean Subjects
Completed NCT01613287 - Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension N/A
Recruiting NCT00372346 - Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension N/A
Withdrawn NCT01645826 - Efficacy Study of Cardizem in Pulmonary Arterial Hypertension N/A
Completed NCT00641836 - Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension N/A
Not yet recruiting NCT06104228 - 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) Phase 2
Recruiting NCT02959723 - Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies N/A
Recruiting NCT01288651 - Iron Deficiency In Pulmonary Hypertension Phase 4
Recruiting NCT05462574 - Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
Completed NCT02565030 - Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome
Active, not recruiting NCT01246037 - Beta-blockers in i-PAH Phase 1/Phase 2
Recruiting NCT01683981 - Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate Phase 0
Completed NCT03069716 - A Mobile Health Intervention in Pulmonary Arterial Hypertension N/A
Completed NCT05767918 - StratosPHere (Non-interventional Study)
Completed NCT00257413 - Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension N/A